|
|
|
| Value and prognostic factors of repeat hepatectomy for recurrent colorectal liver metastasis |
| Jia-Min Zhou a , b , # , Lu Wang a , b , # , An-Rong Mao a , b , ∗ |
a Department of Hepatic Surgery, Shanghai Cancer Center, Fudan University, Shanghai 200032, China
b Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
∗Corresponding author at: Department of Hepatic Surgery, Shanghai Cancer Center, Fudan University, Shanghai 200032, China.
E-mail address: 13020143060@163.com (A.-R. Mao).
# Contributed equally. |
|
|
|
Abstract Background: More than 50% of patients with colorectal cancer develop liver metastases. Hepatectomy is the preferred treatment for resectable liver metastases. This review provides a perspective on the utility and relevant prognostic factors of repeat hepatectomy in recurrent colorectal liver metastasis (CRLM).
Data sources: The keywords “recurrent colorectal liver metastases”, “recurrent hepatic metastases from colorectal cancer”, “liver metastases of colorectal cancer”, “repeat hepatectomy”, “repeat hepatic resection”, “second hepatic resection”, and “prognostic factors”were used to retrieve articles published in the PubMed database up to August 2020. Additional articles were identified by a manual search of references from key articles.
Results: Despite improvements in surgical methods and perioperative chemotherapy, recurrence remains common in 37%–68% of patients. Standards or guidelines for the treatment of recurrent liver metastases are lacking. Repeat hepatectomy appears to be the best option for patients with resectable metastases. The commonly reported prognostic factors after repeat hepatectomy were R0 resection, carcinoembryonic antigen level, the presence of extrahepatic disease, a short disease-free interval between initial and repeat hepatectomy, the number ( > 1) and size ( ≥5 cm) of hepatic lesions, requiring blood transfusion, and no adjuvant chemotherapy after initial hepatectomy. The median overall survival after repeat hepatectomy ranged from 19.3 to 62 months, and the 5-year overall survival ranged from 21% to 73%. Chemotherapy can act as a test for the biological behavior of tumors with the goal of avoiding unnecessary surgery, and a multimodal approach involving aggressive chemotherapy and repeat hepatectomy might be the treatment of choice for patients with early recurrent CRLM.
Conclusions: Repeat hepatectomy is a relatively safe and effective treatment for resectable recurrent CRLM. The presence or absence of prognostic factors might facilitate patient selection to improve short- and long-term outcomes.
|
|
|
|
|
|
|
|
|
2023, Vol. 22 
